Testosterone Therapy & Heart Disease Claims
Turn to Cleveland’s Premier Drug Injury Lawyers at Spangenberg
There is new and important medical research indicating that men using testosterone therapy may be at a significantly increased risk for cardiovascular events, including stroke, pulmonary embolism, or death. Testosterone therapy can come in the form of topical gels, transdermal patches, buccal systems (applied to the upper gum or inner cheek), and injections.
The following products are prescribed for testosterone therapy:
- Topic gels: Androgel, Axiron, Fortesta, Testim
- Patch: Androderm
- Buccal System: Striant
The increase in advertising and pressure from manufacturers to expand their market share has led to the rapid growth of testosterone therapy prescriptions. The demographic for those prescribed low T drugs now include younger men and those who may not have a testosterone deficiency or lack the associated medical condition, or hypogonadism. None of the FDA-approved testosterone products are approved for use in men with low testosterone levels who lack this associated medical condition.
Testosterone Therapy Drugs Can Have Significant Health Risks
Recent studies reported the association between testosterone therapy use and cardiovascular and pulmonary events. A study published in January 2014 noted two groups of men had a greater risk of injury. Men over the age of 65 double their risk of suffering a heart attack during the first 90 days of undergoing testosterone therapy. Men younger than 65 with a pre-existing history of heart disease could face nearly triple the risk of experiencing a serious or fatal complication.
The Journal of the American Medical Association reported findings in November 2013 from a group of men being assessed for coronary artery disease through the U.S. Veteran Affairs health system. On average, the men were 60 years old and many suffered underlying cardiovascular disease. Some of the men were given testosterone therapy medication while others were not. The study suggested a 30% increased risk of stroke, heart attack, and death in the group that had received testosterone therapy.